These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study. Palazzuoli A; Pirrotta F; Cartocci A; Delcuratolo E; Dini FL; Correale M; Dattilo G; Masarone D; Scelsi L; Ghio S; Tocchetti CG; Mercurio V; Brunetti ND; Nodari S; Barillà F; Ambrosio G; Carluccio E Ther Adv Cardiovasc Dis; 2024; 18():17539447241285136. PubMed ID: 39611607 [TBL] [Abstract][Full Text] [Related]
3. Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials. Lu H; Claggett BL; Packer M; Lam CSP; Swedberg K; Rouleau J; Zile MR; Lefkowitz M; Desai AS; Jhund P; McMurray JJV; Solomon SD; Vaduganathan M JAMA Cardiol; 2024 Nov; 9(11):1047-1052. PubMed ID: 39210725 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials. Butt JH; McMurray JJV; Claggett BL; Jhund PS; Neuen BL; McCausland FR; Desai AS; Lam CSP; Pitt B; Pfeffer MA; Packer M; Beldhuis IE; Voors AA; Zannad F; Heerspink HJL; Solomon SD; Vaduganathan M Circulation; 2024 Dec; 150(23):1858-1868. PubMed ID: 39217458 [TBL] [Abstract][Full Text] [Related]
5. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Shaddy R; Burch M; Kantor PF; Solar-Yohay S; Garito T; Zhang S; Kocun M; Mao C; Cilliers A; Wang X; Canter C; Rossano J; Wallis G; Menteer J; Daou L; Kusa J; Tokel K; Dilber D; Xu Z; Xiao T; Halnon N; Daly KP; Bock MJ; Zuckerman W; Singh TP; Chakrabarti M; Levitas A; Senni M; Grutter G; Kim GB; Song J; Lee HD; Chen CK; Sanchez-de-Toledo J; Law Y; Wanitkun S; Cui Y; Anjos R; Mese T; Bonnet D; Circulation; 2024 Nov; 150(22):1756-1766. PubMed ID: 39319469 [TBL] [Abstract][Full Text] [Related]
6. ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation. Sobhy M; Eletriby A; Ragy H; Kandil H; Saleh MA; Farag N; Guindy R; Bendary A; Nayel AME; Shawky A; Khairy A; Mortada A; Zarif B; Badran H; Khorshid H; Mahmoud K; Said K; Leon K; Abdelsabour M; Tawfik M; Abdelmegid MAF; Koriem M; Loutfi M; Wadie M; Elnoamany M; Sadaka M; Seleem M; Zahran M; Amin OA; Elkaffas S; Ayad S; Kilany WE; Ammar W; Elawady W; Elhammady W; Abdelhady Y Cardiol Ther; 2024 Dec; 13(4):707-736. PubMed ID: 39455534 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor-neprilysin inhibition and improved ventricular-arterial coupling in heart failure with reduced ejection fraction. Stegmann T; Parentin L; Schirmer SH; Lavall P; Hagendorff A; Laufs U; Lavall D Am J Physiol Heart Circ Physiol; 2024 Dec; 327(6):H1477-H1489. PubMed ID: 39453422 [TBL] [Abstract][Full Text] [Related]
8. Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4-5 chronic kidney disease. Saka Y; Takahashi H; Naruse T; Watanabe Y Clin Exp Nephrol; 2024 Dec; 28(12):1327-1331. PubMed ID: 39361183 [TBL] [Abstract][Full Text] [Related]
9. The impact of angiotensin-receptor neprilysin inhibitors on cardiovascular events and solute transport function in peritoneal dialysis patients: a multicenter retrospective controlled study. Wang Y; Zhou C; Ma X; Shi Y; Zang X; Bai S; Hu Y; Lv Z; Hong H; Wang Y; Yan D; Yang X; Yu C; Jiang D; Zhuang S; Wang Y; Liu N Ren Fail; 2024 Dec; 46(2):2431637. PubMed ID: 39610019 [TBL] [Abstract][Full Text] [Related]
10. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication. Ryan R; Hill S Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction - Baseline Characteristics and Treatment of PARALLEL-HF Trial. Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Kitamura T; Guo W Circ J; 2018 Sep; 82(10):2575-2583. PubMed ID: 30047502 [TBL] [Abstract][Full Text] [Related]
12. Gestational Diabetes Mellitus: Unveiling Maternal Health Dynamics from Pregnancy Through Postpartum Perspectives. Mora-Ortiz M; Rivas-García L Open Res Eur; 2024; 4():164. PubMed ID: 39355538 [TBL] [Abstract][Full Text] [Related]
13. Clinical Management Strategies of Cardiologists in Heart Failure with Reduced Ejection Fraction in Türkiye. Kocabaş U; Özçalık E; Kıvrak T; Altın C; Türk UÖ Turk Kardiyol Dern Ars; 2024 Dec; 52(8):581-589. PubMed ID: 39620289 [TBL] [Abstract][Full Text] [Related]
14. Primary Medication Adherence in Medicare Beneficiaries Prescribed Sacubitril-Valsartan or Renin-Angiotensin System Blockers for Heart Failure with Reduced Ejection Fraction. Hwang CS; Desai RJ; Kesselheim AS; Levin R; Rome BN Am Heart J; 2024 Dec; ():. PubMed ID: 39638276 [TBL] [Abstract][Full Text] [Related]
15. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. Kuan V; Denaxas S; Patalay P; Nitsch D; Mathur R; Gonzalez-Izquierdo A; Sofat R; Partridge L; Roberts A; Wong ICK; Hingorani M; Chaturvedi N; Hemingway H; Hingorani AD; Lancet Digit Health; 2023 Jan; 5(1):e16-e27. PubMed ID: 36460578 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow? Masarone D; Valente F; Verrengia M; Contaldi C; di Palma V; Falco L; Catapano D; di Lorenzo E J Clin Med; 2024 Nov; 13(22):. PubMed ID: 39598011 [TBL] [Abstract][Full Text] [Related]
17. Role of NLRP3 Inflammasome in Heart Failure Patients Undergoing Cardiac Surgery as a Potential Determinant of Postoperative Atrial Fibrillation and Remodeling: Is SGLT2 Cotransporter Inhibition an Alternative for Cardioprotection? Castillo RL; Farías J; Sandoval C; González-Candia A; Figueroa E; Quezada M; Cruz G; Llanos P; Jorquera G; Kostin S; Carrasco R Antioxidants (Basel); 2024 Nov; 13(11):. PubMed ID: 39594530 [TBL] [Abstract][Full Text] [Related]
18. Unlocking data: Decision-maker perspectives on cross-sectoral data sharing and linkage as part of a whole-systems approach to public health policy and practice. Tweed E; Cimova K; Craig P; Allik M; Brown D; Campbell M; Henderson D; Mayor C; Meier P; Watson N Public Health Res (Southampt); 2024 Nov; ():1-30. PubMed ID: 39582242 [TBL] [Abstract][Full Text] [Related]
19. Qualitative evaluation to understand barriers and facilitators to prescribing angiotensin receptor-neprilysin inhibitors (ARNi) and sodium-glucose cotransporter inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF). Pradhan AM; Lussier ME; Nguyen M; Voyce SJ; Wright EA J Am Pharm Assoc (2003); 2024; 64(6):102224. PubMed ID: 39209218 [TBL] [Abstract][Full Text] [Related]